Related Experiment Video
Updated: May 3, 2026

08:40
An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
Published on: March 14, 2016
19.0K
Understanding IFNλ in rheumatoid arthritis
Arthritis Research & Therapy
|January 22, 2014
Summary
Type III interferons, specifically interferon lambda 1 (IFNλ1), boost inflammatory responses in rheumatoid arthritis by increasing Toll-like receptor expression. This finding offers new insights into rheumatoid arthritis pathogenesis and potential therapeutic targets.
Area of Science:
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) pathogenesis involves complex inflammatory mechanisms.
- Type I interferons' role in RA is established, but Type III interferons (IFNλ) remain understudied.
Discussion:
- Interferon lambda 1 (IFNλ1), a Type III interferon, was investigated for its effects on RA inflammatory pathways.
- The study examined how IFNλ1 influences fibroblast function and cytokine production in the context of RA.
Key Insights:
- IFNλ1 enhances Toll-like receptor (TLR) expression on cells involved in RA.
- This enhancement by IFNλ1 leads to increased production of pro-inflammatory cytokines crucial for RA initiation and maintenance.
Outlook:
- Understanding IFNλ's role provides new avenues for RA therapeutic development.
- Targeting the IFNλ pathway could offer novel strategies for managing rheumatoid arthritis inflammation.
More Related Videos
Related Concept Videos
T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
NF-κB-dependent Signaling Pathway
7.6K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.6K
Chronic Inflammation: Introduction
41
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
41
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K

